Cyclacel Pharmaceuticals, Inc. (CYCC) financial statements (2022 and earlier)

Company profile

Business Address 200 CONNELL DRIVE
BERKELEY HEIGHTS, NJ 07922
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments36,55933,40611,88517,50423,91016,52020,440
Cash and cash equivalents36,55933,40611,88517,50423,91016,52020,440
Receivables   356434 326
Prepaid expense  703543363867893
Disposal group, including discontinued operation      75
Deposits current assets   66132132132
Other current assets79661031708141 
Other undisclosed current assets4,3041,9971,3261,1481,0542,0572,700
Total current assets:40,94235,46914,01719,78725,97419,61724,566
Noncurrent Assets
Operating lease, right-of-use asset301,2271,264
Property, plant and equipment6410627362945198
Deposits noncurrent assets1,551      
Total noncurrent assets:1,6451,3331,291362945198
TOTAL ASSETS:42,58736,80215,30819,82326,00319,66224,764
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,2942,4862,4204,4514,1135,2595,678
Accounts payable2,1175148902,7191,5582,4971,940
Accrued liabilities3,1771,9721,5301,7322,5552,7623,738
Disposal group, including discontinued operation      75
Total current liabilities:5,2942,4862,4204,4514,1135,2595,753
Noncurrent Liabilities
Long-term debt and lease obligation301,0571,191    
Operating lease, liability301,0571,191
Liabilities, other than long-term debt    124130176
Other liabilities    124130176
Other undisclosed noncurrent liabilities(30)  100   
Total noncurrent liabilities:301,0571,191100124130176
Total liabilities:5,3243,5433,6114,5514,2375,3895,929
Stockholders' equity
Stockholders' equity attributable to parent37,26333,25911,69715,27221,76614,27318,835
Common stock106171212435
Additional paid in capital422,960400,071370,126365,817365,057350,051342,555
Accumulated other comprehensive loss(748)(746)(819)(760)(794)(743)(596)
Accumulated deficit(384,959)(366,072)(357,627)(349,797)(342,509)(335,039)(323,159)
Total stockholders' equity:37,26333,25911,69715,27221,76614,27318,835
TOTAL LIABILITIES AND EQUITY:42,58736,80215,30819,82326,00319,66224,764

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues   150 8431,944
Revenue, net 8431,944
Cost of revenue  (38)  (12) 
Gross profit:  (38)150 8311,944
Operating expenses(22,938)(10,636)(9,644)(9,698)(9,491)(14,981)(18,114)
Operating loss:(22,938)(10,636)(9,682)(9,548)(9,491)(14,150)(16,170)
Nonoperating income (expense)2049555569231,028376(316)
Investment income, nonoperating1642224331118379
Foreign currency transaction gain (loss), before tax4422101(90)(39)273(368)
Other nonoperating income1448912316829496694
Loss from continuing operations before income taxes:(22,734)(9,681)(9,126)(8,625)(8,463)(13,774)(16,486)
Income tax benefit3,8471,2361,2961,3379931,9832,144
Net loss attributable to parent:(18,887)(8,445)(7,830)(7,288)(7,470)(11,791)(14,342)
Preferred stock dividends and other adjustments(201)(3,976)(201)(201)(201)(200) 
Other undisclosed net loss available to common stockholders, basic      (201)
Net loss available to common stockholders, basic:(19,088)(12,421)(8,031)(7,489)(7,671)(11,991)(14,543)
Other undisclosed net loss available to common stockholders, diluted    (7,175)  
Net loss available to common stockholders, diluted:(19,088)(12,421)(8,031)(7,489)(14,846)(11,991)(14,543)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(18,887)(8,445)(7,830)(7,288)(7,470)(11,791)(14,342)
Comprehensive loss:(18,887)(8,445)(7,830)(7,288)(7,470)(11,791)(14,342)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2)73(59)34(51)  
Comprehensive loss, net of tax, attributable to parent:(18,889)(8,372)(7,889)(7,254)(7,521)(11,791)(14,342)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: